言語を選択

KIR2DL1

KIR2DL1 詳細

英語名	Killer cell immunoglobulin-like receptor 2DL1	市販薬剤の数	0
治験薬の数	1	ターゲットの別称	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
研究＆開発段階	Phase 2 Clinical

英語名	Killer cell immunoglobulin-like receptor 2DL1
ターゲットの別称	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
市販薬剤の数	0
治験薬の数	1
研究＆開発段階	Phase 2 Clinical

KIR2DL1 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
Fc Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
KI1-H5255	Human	HEK293	Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag

総数量1

KIR2DL1バックグランド

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

KIR2DL1分子の別称

CD158a

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	詳細